Myasthenia gravis (MG) is a disease of the neuromuscular junction characterised by weakness and fatigability of skeletal muscle. The basic defect is a reduction in the number of functional acetylcholine receptors (AChRs) ' 2 resulting in reduced amplitude of the miniature end-plate potentials.3 This is due to the presence of anti-AChR antibodies which are detectable in 85-90% of MG patients,4 as determined by immunoprecipitation of solubilised human AChR labelled with radioactive alphabungarotoxin (a-butx), a snake toxin which binds specifically and irreversibly to muscle AChR (see ref 5 ).
The pathogenic role of anti-AChR was demonstrated by the passive transfer of MG to mice using IgG purified from MG patients6 7 and is indicated by $ :V the correlation between anti-AChR levels and clinical state during treatment of the disease in an individual.8 Anti-AChR is thought to cause a loss of postsynaptic AChR by several mechanisms which include complement-induced postsynaptic lysis9 and an increased rate of AChR degradation: MG sera or IgG were shown to accelerate degradation of '25I a-butx-labelled AChR in mammalian skeletal muscle cultures'01 and to increase the rate of degradation of AChRs at the endplates of mice injected with MG IgG. ' 
Measurement ofAChR half-life in vivo
The technique used was similar to that described by Berg and Hall,15 Chang and Huang'6 and Stanley and Drachman." Groups of mice were anaesthetised with halothane, and given a single intrapleural injection of 125I-a-butx into the left hemi-thorax (0-1 ug/g body weight in a total volume of 70 ,ul of Ringer lactate solution). The amount injected was determined by preliminary experiments and was chosen to bind to approximately 90% of the total available AChR sites. Four hours later (time "0") a group of mice were killed, their diaphragms removed and washed for two hours at room temperature and then overnight at 4°C in pre-oxygenated Ringer lactate solution. The muscles were fixed in 70% Ringer and 5% glutaraldehyde, and the radioactivity associated with the end-plate region measured as above. Groups of animals were killed at intervals over the next 2-10 days, and the binding to the endplate region expressed as a percentage of the amount present at time "0" and plotted on a semi log scale against time.
Groups of animals (10-12), injected with a-butx as above, were given daily injections of 15 mg of IgG intraperitoneally from an individual MG or control preparation starting at time "0". Two animals were killed at each time interval over the next 2-10 days and the decline in end-plate radioactivity measured as above.
A straight line was drawn through the points on the semi-log plots using the method of linear regression, and any difference between the slope of the line in MG IgG treated and control animals was assessed by Student's t test. The fractional degradation rate K can be given by ln 2/t1/2 where t½/2 was the time in days, taken from the semilog plots, by which the radioactivity had declined to 50% of the starting value. Results are expressed as t1/2 values.
Measurement of dissociation of 125a-butx from mouse endplates The contribution of dissociation of a-butx from the labelled diaphragms to the total loss of 251I-a-butx in vivo was assessed by in vitro culture of '251-a-butx labelled diaphragms in the presence of 10% control IgG or MG IgG (MG7 and MG10) for 72 hours at 37°C. 0-2 nM dinitrophenol was added to prevent active degradation.
Calculation of the predicted number of AChRs 
Results
Serum anti-AChR titres in the ten MG patients measured against human receptor gave little indication of the titre measured against mouse AChR (tables 1 and 2) which varied considerably for both species (r = 0-57, ns) although it was very similar between the two mouse strains. There was, however, some correlation between the titre measured against degradation. Reversibility of a-butx was only 5% of the total bound during this period and was not greater in the presence of MG IgG preparations 7 
